Index

ALIFE trial, 73
allogeneic lymphocyte immunization, 66–8
American Society of Reproductive Medicine, 4
antiphospholipid antibodies, 53–4, 147–8
antiphospholipid syndrome (APS), 11–12, 27, 147–8
antithyroid antibodies, 119–20
Ashermann’s syndrome, 121–2
aspirin, 71–3
assisted reproductive technology (ART), 51
after IVF/ICSI, 130–132
after OI with or without IUI, 129–30
group I & II RM patients, 128–9
sperm-related factors, 130
treatment, 132–4
Association of Early Pregnancy Units (AEPUs), 158
biochemical pregnancies see pregnancies of unknown location (PULs)
biophysical profile (BPP), 116
BMI, 2, 96
bone mineral density (BMD), 123
British Society for Haematology, 125
cardiotocography (CTG), 116
cervical length surveillance, 111–12
cchorionic bumps, 109
cchorionic villus sampling (CVS), 111
comboxiclav, 117
cognitive behavioral therapy, 144–5
crown rump length (CRL), 107–8
cytokines and pregnancy
CD4 T-helper (Th) cells, 38–9
cytokine gene polymorphisms and RPL, 42–3
cytokines evaluation, RPL diagnosis, 43–4
healthy pregnancy vs. RPL
cytokine profile, 40–41
Treg cells, Th17 cells, and cytokines interaction, 41–2
pro-inflammatory IL-1 mediators, 39–40
Dawes–Redman criteria, 116
doppler blood flow, 116
dual energy x-ray absorptiometry (DEXA) scans, 123
eye early pregnancy unit see recurrent miscarriage clinics

ectopic pregnancy, 165–6
emergency assessment units (EAUs), 157–8
estrogen, 76
factor V Leiden mutation, 12
fetal fibronectin (fFN), 117
fetal heartbeat (FH), 107–9
fetal karyotyping see parental and fetal karyotyping
fetal pole, 107–8
fibroids, 121
first trimester screening, 110–111
G20210A mutation see prothrombin gene mutation
gestation sac (GS), 107–8
GM-CSF/G-CSF treatment, 81–2
HABENOX trials, 73
hematopoietic cytokines see GM-CSF/G-CSF treatment
heparin, 71–3
heparin-induced thrombocytopenia (HIT), 123
HepASA trial, 73
2 hit hypothesis, 152
human chorionic gonadotropin (HCG), 80–81, 106
human leukocyte antigens (HLAs), 55
hysterosalpingography (HSG), 130
idiopathic RM, 49, 168
immune therapy, 34–5
inherited thrombophilia, 11–13, 27, 124–5
intramural or subserous fibroids, 121
intrauterine fetal death (IUFD), 116
intravenous immunoglobulin (IVIg) treatment, 8–9, 68–9
investigational new drug (IND), 67
in vitro fertilization (IVF) procedure, 62
IVF/ICSI treatment, 83–4, 130–132
Kaplan–Meier curves, 153
leukemia inhibitory factor (LIF), 39–40
low molecular weight heparin (LMWH), 14–16
luteal phase deficiency (LPD), 105

© 2014 John Wiley & Sons, Ltd. Published 2014 by John Wiley & Sons, Ltd.
Manning criteria, 116
metformin, 78–80
metroplasty, 23
Müllerian (paramesonephric) ducts, 21
multifetal pregnancy, 109–10
National Confidential Enquiry into Patient Outcome and Death, 157
natural killer (NK) cells
benefits, 30
flow cytometric analysis, 31–2
immune therapy, 34–5
immunohistochemistry, 31
prognosis in RPL, 55
and reproduction, 30
in RM, 32–3
testing in practice, 33–4
nuchal translucency (NT), 110
ORACLE trial, 117
parental and fetal karyotyping
irrelevant diagnostic investigations, 26–7
parental chromosomal aberrations, 52–3
parental chromosome abnormalities, 17–18
postnatal karyotyping, 18
prognostic value and treatment, 20
reproductive consequences of carrier status, 18–19
testing the fetal karyotype, 19–20
treatment or prevention, 19
peripheral blood mononuclear cultures (PBMC), 4
polycystic ovary syndrome (PCOS), 120, 129–30
postnatal karyotyping, 18
prednisolone, 75–6
pregnancies of unknown location (PULs), 4–5, 104, 106
preimplantation genetic diagnosis (PGD)
aim, 19, 62
allele dropout, 63
impact in RM couples, 63–4
PCR and FISH, 62
preimplantation genetic screening (PGS), 64–5
premature prelabor rupture of membranes (PPROM), 109, 117–18
primary antiphospholipid syndrome
anti Ro/SS-A and anti La/SS-B antibodies, 124
diagnosis and treatment, 122
risks of treatment, 123–4
uterine artery Doppler, 122
progesterone, 73–5, 105–6
prognosis
assessment in RM
antiphospholipid antibodies, 53–4
concurrent infertility, 51–2
hereditary thrombophilias, 54–5
immunological factors, 55
karyotype of previous miscarriage, 51
late pregnancy losses, 52
maternal age, 50–51
number of miscarriages, 50
parental chromosomal rearrangement, 52–3
primary, secondary, or tertiary aborter status, 52
psychological stress, 57
sperm defects, 57
thyroid dysfunction, 56
uterine anomalies, 56–7
classification of
good prognosis, 59
medium prognosis, 59
poor prognosis, 59–60
relative prognoses, 58
predictive factors affecting, 47
in pregnancy, 57–8
risk factors, 48
PROMISE trial, 74, 112
prothrombin gene mutation, 12
psychological stress, 57
RCOG Green-top guidelines, 89
recurrent miscarriage (RM)
active and passive immunization
allogeneic lymphocyte immunization, 66–8
intravenous immunoglobulin (IvIg), 68–9
after ART (see assisted reproductive technology (ART))
and aPL, 147–8
and autoimmunity, 147
best possible chance for a healthy pregnancy, 94–6
chlamydial pelvic inflammation case, 184–5
cytokine gene polymorphisms (see cytokines and pregnancy)
demographic data collection
BMI, 2
high-maternal age, 2
lifestyle factors, 2–3
occupational factors, 3
partner, 3
social class, 3
diagnostic investigations testing
(see thrombophilia; thyroid autoimmunity; thyroid hormone disorders; uterine anomalies)
disease history, 7
eye pregnancy discussion, 89
eye pregnancy unit (see recurrent miscarriage clinics)
endocrine and ultrasonic surveillance
first trimester screening, 110–111
human chorionic gonadotropin (HCG), 106
prediction of miscarriage, 108–9
progesterone, 105, 112
role of, 104, 107
second trimester screening, 111–12
subchorionic hematoma, 109
supportive care, 112–13
vanishing twin syndrome (VTS), 109–10
estrogen treatment, 76
family history, 7
GM-CSF/G-CSF treatment, 81–2
growth-retarded boy in GW22, 185–6
hCG treatment, 80–81
heparin and aspirin treatment, 71–3
importance of good care, 97–8
inherited thrombophilia, 124–5
metformin treatment, 78–80
miscarriage case in GW7, 182–4
NK cell testing (see natural killer (NK) cells)
other autoantibodies, 148–9
polycystic ovary syndrome (PCOS), 120
PPROM management, 117–18
preconceptual discussion, 88–9
prednisolone treatment, 75–6
preimplantation genetic testing (see preimplantation genetic diagnosis (PGD); preimplantation genetic screening (PGS))
prematurity prevention, 117
primary antiphospholipid syndrome
anti Ro/SS-A and anti La/SS-B antibodies, 124
diagnosis and treatment, 122
risks of treatment, 123–4
uterine artery Doppler, 122
private clinics, 181
progesterone treatment, 73–5
prognosis assessment
antiphospholipid antibodies, 53–4
concurrent infertility, 51–2
heritable thrombophilias, 54–5
immunological factors, 55
karyotype of previous miscarriage, 51
late pregnancy losses, 52
maternal age, 50–51
number of miscarriages, 50
parental chromosomal rearrangement, 52–3
primary, secondary, or tertiary aborter status, 52
psychological stress, 57
sperm defects, 57
thyroid dysfunction, 56
uterine anomalies, 56–7
questions about, 89–93
randomized-controlled trials (RCTs), 180–181
reproductive history
clinical appearance of pregnancy losses, 4–5
gestational age of pregnancy losses, 5
perinatal data, 5–6
risk and cause, 96–7
and risk of autoimmune disease, 149
setting realistic expectations, 93–4
sources of information and support, 99–100
spontaneous preterm labor prediction, 117
standard IVF/ICSI treatment, 83–4
steps to reduce risk
knowledge about miscarriage, 86
understanding the emotional and social impact, 87–8
updated knowledge, 87
stress and depression in women
anxiety and depression, 136–7
clinicians assistance, 142
clinicians improve coping, 142–3
decision making, 140–141
grieving process, 137–8
Infertility Centers emotional supports, 143–4
lonely experience, 138–140
much more than a medical condition, 135–6
structural uterine abnormalities
Ashermann’s syndrome, 121–2
fibroids, 121
uterine septum, 120–121
talking to patients, 97
third trimester screening
chromosomal abnormalities, 118
fetal well-being tests, 116
and thromboembolic disease
hemostatic changes, 150
Index

RCOG Green-top guidelines (cont’d)
nonpregnant women in a prothrombotic state, 150–152
risk of thrombotic events, 152–4
thromboprophylaxis, 154–5
thyroid hormone disorders
antithyroid antibodies, 119–20
pathology, 119
TBG and TSH, 118–19
TNF-α inhibitors treatment, 82–3
unexplained RM, 126
when trying stops, 100
women with HLA-DQ*0501, 187

recurrent miscarriage clinics
audit and research, 170–171
early pregnancy loss
diagnosis, 160
management, 160–161
ectopic pregnancy, 165–6
expectant management of miscarriage, 164–5
interprofessional approach, 175
investigation protocol for RM, 167
managing patient flow, 176–7
medical management
contraindications, 161–2
protocol for, 162–3
offers other than medical care, 177
patient population at
healthcare providers, 173
multidisciplinary team approach, 173–4
serving the team, 173–4
physical facility, 177–8
positive patient experience, 167
roles of healthcare providers, 175
setting the scene, 158
specialist training, 170
staffing and training implications, 166–9
standards of practice, 159–60
success prediction matrix for idiopathic RM, 168
surgical management of miscarriage, 163–4
ultrasound unit, 178–9

recurrent pregnancy loss (RPL) see recurrent miscarriage (RM)
relaxation training, 144
Rotterdam criteria, 120
Royal College of Obstetricians and Gynaecologists (RCOG), 25, 108

second trimester screening, 111–12
septate uterus, 21–2, 27
shared decision making, 141–2
spontaneous preterm labor, 117
sperm defects, 57
subchorionic hematoma, 109
submucous fibroids, 121
superoxide, 134

TABLET trial, 119
Th1 and Th2 intracellular cytokine assay, 44
thromboembolic disease
hemostatic changes, 150
nonpregnant women in a prothrombotic state, 150–152
risk of thrombotic events, 152–4
thromboprophylaxis, 154–5
thrombophilia
anticoagulant therapy, 14–16
antiphospholipid syndrome, 11–12
association between pregnancy complications and, 14–15
hereditary, 54–5
inherited thrombophilias
blood coagulation and fibrinolysis, 12–13
diagnosis, 11
pathophysiological mechanisms, 13–14
screening in women with RM, 16
thromboprophylaxis, 154–5
Th1/Th2 hypothesis, 40
thyroid autoimmunity
definition, 24
and pregnancy outcomes, 25
research on, 25
screening for, 25–6
treatment with levothyroxine, 25
thyroid function tests (TFTs), 119
thyroid hormone disorders, 23–4, 56
antithyroid antibodies, 119–20
pathology, 119
TBG and TSH, 118–19
thyroid peroxidase antibody (TPOAb), 119
thyroxine binding globulin (TBG), 118–19
TNF-α inhibitors treatment, 82–3

unicorne and bicornuate uterus, 22
uterine anomalies
congenital uterine anomalies, 21
diagnosis of, 22
and pregnancy outcomes, 22
prognosis assessment, 56–7
treatment of, 22–3
uterine natural killer (uNK) cells, 75

vanishing twin syndrome (VTS), 109–10
venous thromboembolism (VTE), 11